What is she best known for?
The fields of study she is best known for:
- Internal medicine
- Cancer
- Disease
Deborah P. Lubeck spends much of her time researching Prostate cancer, Prostate, Prostate-specific antigen, Internal medicine and Surgery.
Prostate cancer is a subfield of Cancer that Deborah P. Lubeck explores.
In the subject of general Cancer, her work in T-stage is often linked to Database, thereby combining diverse domains of study.
Her Internal medicine study incorporates themes from Gynecology and Oncology.
Her Oncology research includes elements of Neoadjuvant therapy, Androgen deprivation therapy, Localized disease and Brachytherapy.
Her studies deal with areas such as Proportional hazards model, Cohort and Surrogate endpoint as well as Radiation therapy.
Her most cited work include:
- The Changing Face of Low-Risk Prostate Cancer: Trends in Clinical Presentation and Primary Management (508 citations)
- Surrogate End Point for Prostate Cancer–Specific Mortality After Radical Prostatectomy or Radiation Therapy (448 citations)
- Outcomes of self‐help education for patients with arthritis (401 citations)
What are the main themes of her work throughout her whole career to date?
Deborah P. Lubeck focuses on Internal medicine, Prostate cancer, Oncology, Cancer and Prostate.
Her Prostate cancer research incorporates themes from Surgery, Gynecology and Quality of life.
Her Oncology study combines topics from a wide range of disciplines, such as Adverse effect and Docetaxel.
When carried out as part of a general Cancer research project, her work on Watchful waiting and Epidemiology of cancer is frequently linked to work in Database, therefore connecting diverse disciplines of study.
The study incorporates disciplines such as Hormonal therapy and Localized disease in addition to Prostate.
The Prostatectomy study combines topics in areas such as Stage, Radiation therapy and Urology.
She most often published in these fields:
- Internal medicine (43.33%)
- Prostate cancer (40.56%)
- Oncology (27.22%)
What were the highlights of her more recent work (between 2007-2020)?
- Internal medicine (43.33%)
- Oncology (27.22%)
- Non small cell (5.00%)
In recent papers she was focusing on the following fields of study:
Her scientific interests lie mostly in Internal medicine, Oncology, Non small cell, Extensive Disease and Disease.
Her research integrates issues of Gastroenterology and Cardiology in her study of Internal medicine.
Her biological study spans a wide range of topics, including Regimen, Surgery and Clinical trial.
Her Disease research is multidisciplinary, incorporating elements of Pediatrics, Newborn screening, Life expectancy and Extrahepatic Cholangiocarcinoma.
Her studies in Gerontology integrate themes in fields like Fee-for-service, Cohort study, Gynecology, Prostate cancer and Preferred provider organization.
Deborah P. Lubeck has included themes like Multivariate analysis, Quality of life and Population study in her Cancer study.
Between 2007 and 2020, her most popular works were:
- Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC) (61 citations)
- Second-line and Third-line Chemotherapy for Lung Cancer: Use and Cost (44 citations)
- Economic evaluation of rituximab plus cyclophosphamide, vincristine and prednisolone for advanced follicular lymphoma (35 citations)
In her most recent research, the most cited papers focused on:
- Internal medicine
- Cancer
- Disease
Her primary areas of study are Internal medicine, Oncology, Cancer, Surgery and Disease.
Her Internal medicine study focuses mostly on Docetaxel, Lung cancer, Regimen and Erlotinib Hydrochloride.
Her Cancer study integrates concerns from other disciplines, such as Incidence, Gerontology, First line and Non small cell, Extensive Disease.
Her work carried out in the field of Gerontology brings together such families of science as Prevalence, Clinical study design, Systematic review and Pediatrics.
The various areas that Deborah P. Lubeck examines in her Surgery study include Adverse effect and Erlotinib.
Her Disease research is multidisciplinary, incorporating perspectives in Mortality rate, Demography, Newborn screening, Life expectancy and Cohort.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
